NAV

Aramchol

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Aramchol
DrugBank Accession Number
DB11860
Background

Aramchol has been used in trials studying the treatment of HIV, Gallstones, Fatty Liver, Metabolic Syndrome, and Nonalcoholic Steatohepatitis, among others.

Type
Small Molecule
Groups
Investigational
Structure
Similar Structures
Weight
Average: 702.118
Monoisotopic: 701.595824648
Chemical Formula
C44H79NO5
Synonyms
Not Available
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
Aluminium phosphateThe serum concentration of Aramchol can be decreased when it is combined with Aluminium phosphate.
Aluminum chlorideThe serum concentration of Aramchol can be decreased when it is combined with Aluminum chloride.
Aluminum chlorohydrateThe serum concentration of Aramchol can be decreased when it is combined with Aluminum chlorohydrate.
Aluminum hydroxideThe serum concentration of Aramchol can be decreased when it is combined with Aluminum hydroxide.
Aluminum oxideThe serum concentration of Aramchol can be decreased when it is combined with Aluminum oxide.
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as dihydroxy bile acids, alcohols and derivatives. These are compounds containing or derived from a bile acid or alcohol, and which bears exactly two carboxylic acid groups.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Bile acids, alcohols and derivatives
Direct Parent
Dihydroxy bile acids, alcohols and derivatives
Alternative Parents
Pregnane-type alkaloids / 12-hydroxysteroids / 7-hydroxysteroids / Azasteroids and derivatives / Alkaloids and derivatives / N-acyl amines / Secondary carboxylic acid amides / Secondary alcohols / Cyclic alcohols and derivatives / Monocarboxylic acids and derivatives
show 6 more
Substituents
12-hydroxysteroid / 7-hydroxysteroid / Alcohol / Aliphatic homopolycyclic compound / Alkaloid or derivatives / Azasteroid / Carbonyl group / Carboxamide group / Carboxylic acid / Carboxylic acid derivative
show 18 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
QE1Q24M65Y
CAS number
246529-22-6
InChI Key
SHKXZIQNFMOPBS-OOMQYRRCSA-N
InChI
InChI=1S/C44H79NO5/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-40(48)45-34-27-28-43(3)33(29-34)30-38(46)42-36-25-24-35(32(2)23-26-41(49)50)44(36,4)39(47)31-37(42)43/h32-39,42,46-47H,5-31H2,1-4H3,(H,45,48)(H,49,50)/t32-,33+,34+,35-,36+,37+,38-,39+,42+,43+,44-/m1/s1
IUPAC Name
(4R)-4-[(1S,2S,5S,7S,9R,10R,11S,14R,15R,16S)-9,16-dihydroxy-5-icosanamido-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]pentanoic acid
SMILES
CCCCCCCCCCCCCCCCCCCC(=O)N[C@H]1CC[C@@]2(C)[C@H](C[C@@H](O)[C@H]3[C@@H]4CC[C@H]([C@H](C)CCC(O)=O)[C@@]4(C)[C@@H](O)C[C@H]23)C1

References

General References
Not Available
PubChem Compound
18738120
PubChem Substance
347828199
ChemSpider
18995061
Wikipedia
Aramchol

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3SuspendedTreatmentCoronavirus Disease 2019 (COVID‑19) / Non Alcoholic Steatohepatitis (NASH)1
2CompletedTreatmentFatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentFatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD / Non Alcoholic Steatohepatitis (NASH) / Syndrome, Metabolic1
2CompletedTreatmentFatty Liver / Liver Disease / Liver Fibroses / Non Alcoholic Steatohepatitis (NASH)1
2Not Yet RecruitingTreatmentPrimary Sclerosing Cholangitis (PSC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility7.83e-05 mg/mLALOGPS
logP8.31ALOGPS
logP10.45Chemaxon
logS-7ALOGPS
pKa (Strongest Acidic)4.48Chemaxon
pKa (Strongest Basic)-0.088Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count4Chemaxon
Polar Surface Area106.86 Å2Chemaxon
Rotatable Bond Count23Chemaxon
Refractivity204.73 m3·mol-1Chemaxon
Polarizability90.31 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-0000001900-e539f09784ffa98bdaff
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0zgl-9111107500-1c874edcbbaef731a915
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-0010003900-9663ae44136cd19ae011
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0f8c-9300037300-89149c0a905552144ef4
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0f6t-2060339300-c187997d0b1fd27e59da
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-9210100000-e93124f9a103cd8dd684
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-334.0122059
predicted
DarkChem Lite v0.1.0
[M-H]-264.81702
predicted
DeepCCS 1.0 (2019)
[M+H]+332.0944059
predicted
DarkChem Lite v0.1.0
[M+H]+266.47018
predicted
DeepCCS 1.0 (2019)
[M+Na]+332.2353059
predicted
DarkChem Lite v0.1.0
[M+Na]+272.627
predicted
DeepCCS 1.0 (2019)

Drug created at October 20, 2016 20:54 / Updated at June 12, 2020 16:53